Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Exosome-Based Early Pancreatic Cancer Detection

On December 5, 2023, Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.  Known as a “silent killer,” approximately 80% of pancreatic cancer patients discover the disease in late stages when it has already spread and cannot be surgically removed. Of these patients, almost none are still living five years after diagnosis. However, the 5-year survival rate increases to at least 44% if the disease is discovered when the cancer is still localized and diagnosed in the early stages. Biological Dynamics’ ExoVita Pancreas assay has demonstrated the ability to detect cancer at stages I and II with 93% sensitivity and 91% specificity.

Login Or Register To Read Full Story